Henlius Biotech Shares Surge After Fosun's Buyout Offer
By Tracy Qu
Shanghai Henlius Biotech shares rose after it agreed to a buyout offer by Chinese conglomerate Fosun International in a deal valuing the Hong Kong-listed drugmaker at US$1.7 billion.
Shares of Henlius were 19% higher at 22.40 Hong Kong dollars by midday Tuesday, taking gains this year to 61%. Fosun International shares added 0.2%, while the benchmark Hang Seng Index was 0.45% higher.
Fosun International, one of China's biggest listed conglomerates, said late Monday that it will offer HK$24.60 for each Henlius share through its unit Shanghai Fosun Pharmaceutical, Henlius's controlling shareholder. The offer represents a 31% premium to Henlius's closing price on May 22 before the company halted trading pending takeover and merger-related news.
The deal values Henlius at about HK$13.37 billion (US$1.71 billion). Fosun, which said it plans to merge Henlius with Shanghai Fosun Pharmaceutical, said the drugmaker's listing status "no longer provides meaningful access to capital," adding that "unsatisfactory share performance" distracted the company from its business operations.
Henlius shares are trading at less than half the company's initial public offering level in 2019.
Write to Tracy Qu at tracy.qu@wsj.com
(END) Dow Jones Newswires
June 25, 2024 00:47 ET (04:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks